NEJM Journal Watch - General Medicine

Duration of Benefit for Dual Antiplatelet Therapy After Mild Ischemic Stroke or Transient Ischemic Attack

Benefits are front-loaded, while bleeding risks are constant.

Is Montelukast Effective for Chronic Urticaria?

Modest benefit might be seen when this drug is added to antihistamines.

Catching Inpatient Diagnostic Errors at Change of Shift

A change to the differential diagnosis by an incoming hospitalist uncovered errors in one third of patients.

Atorvastatin vs. Rosuvastatin: Do Effectiveness and Safety Differ?

In this observational study, rosuvastatin was associated with lower 6-year mortality but interpreting and applying the results is not straightforward.

Should We Still Be Using Albuterol Alone for Asthma?

The combinations of inhaled steroid/albuterol or inhaled steroid/formoterol clearly are superior to monotherapy for rescue.

Is Prostate Cancer Overtreatment on the Rise?

A cohort study points to increasing overtreatment of intermediate- and high-risk prostate cancer among men with limited life expectancy.

Tirzepatide in Patients with Obesity and Prediabetes

During a 3-year study, most patients reverted to normoglycemia.

To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?

Closure of the atrial appendage was superior to oral anticoagulation in safety and noninferior in effectiveness.

Fezolinetant for Vasomotor Symptoms in Women for Whom Hormone Therapy Isn't an Option

Fezolinetant appeared effective and safe in this population through 24 weeks.

Observe or Treat Early-Stage Chronic Lymphocytic Leukemia?

In patients with Binet stage A disease and risk factors for early progression, ibrutinib was associated with delayed onset of symptoms but no survival benefit.